Genentech presents data from two Phase II trials

DNA reported data from a 99-patient, open-label study of its recombinant humanized monoclonal antibody against vascular endothelial growth factor (rhuMAb-VEGF) with carboplatin/paclitaxel to treat non-small cell lung cancer.

Read the full 283 word article

How to gain access

Continue reading with a
two-week free trial.